The Poly-ICLC ATL-DC combo study has not even reached primary completion. The trial still asserts an estimated 60 patients, so possibly they plan to reopen enrollment. Maybe they want to use DCvax-L for the rest but cannot get it?
Does this have any relation to NWBO? Can NWBO clarify?
P.S.: It is not a formulation. The drugs are being used in combo. The term formulation implies they are mixed together as part of the single drug. Ha very important difference wrt approval. There has been no clinic trial using any such formulation, and fr from clear any future trial would, different injection sites for the 2.
News 
Market Data 
Discover 
